Remission · Participants with Crohn's disease in remission
It is very uncertain whether budesonide 6‐9 mg changes continued remission at 12 months compared with azathioprine 2‐2.5 mg/kg (very low certainty).
1 finding from 1 review
Clinical improvement (dichotomous) · active EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement (continuous) · active EoE patients
1 finding from 1 review
Histological improvement (dichotomous) · active EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Histological improvement (continuous) · active EoE patients
1 finding from 1 review
Endoscopic improvement (dichotomous) · active EoE patients
1 finding from 1 review
Endoscopic improvement (continuous) · active EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · active EoE patients
1 finding from 1 review
Remission (combined clinical and endoscopic remission) · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg probably leads to higher remission (combined clinical and endoscopic remission) compared with placebo (moderate certainty).
1 finding from 1 review
Endoscopic improvement (dichotomous) · Adult patients with active ulcerative colitis
Budesonide MMX® 6 mg showed no clear difference in endoscopic improvement compared with placebo (moderate certainty).
1 finding from 1 review
Histologic remission · Adult patients with active ulcerative colitis
Budesonide MMX® 6 mg showed no clear difference in histologic remission compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · Adult patients with active ulcerative colitis
Budesonide MMX® 6 mg showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Adverse events · Adult patients with active ulcerative colitis
It is very uncertain whether budesonide MMX® 6 mg changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Adult patients with active ulcerative colitis
Budesonide MMX® 6 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Clinical improvement · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg showed no clear difference in clinical improvement compared with placebo (moderate certainty).
1 finding from 1 review
Remission (combined clinical and endoscopic remission) · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg showed no clear difference in remission (combined clinical and endoscopic remission) compared with entocort EC 9mg (low certainty).
1 finding from 1 review
Endoscopic improvement (dichotomous) · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg probably leads to higher endoscopic improvement compared with placebo (moderate certainty).
1 finding from 1 review
Clinical improvement · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg showed no clear difference in clinical improvement compared with entocort EC 9mg (moderate certainty).
1 finding from 1 review
Endoscopic improvement (dichotomous) · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg showed no clear difference in endoscopic improvement compared with entocort EC 9mg (moderate certainty).
1 finding from 1 review
Histologic remission · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg showed no clear difference in histologic remission compared with entocort EC 9mg (low certainty).
1 finding from 1 review